Skip to main content

Table 4 Association between brain response and systemic response in patients with brain metastasis at study entry

From: Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea

Best Systemic Response

Best Brain Response

CR

PR

Any response

SD > 6 m

SD < 6 m

PD

Total

P-value*

No

(%)

No

(%)

No

(%)

No

(%)

No

(%)

No

(%)

No

(%)

 

CR

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

0

(0.0)

0.0001

PR

1

(50.0)

2

(33.3)

12

(60.0)

2

(25.0)

0

(0.0)

1

(14.3)

18

(38.3)

 

SD > 6 m

0

(0.0)

0

(0.0)

3

(15.0)

6

(75.0)

1

(25.0)

0

(0.0)

10

(21.3)

 

SD < 6 m

1

(50.0)

4

(66.7)

3

(15.0)

0

(0.0)

3

(75.0)

2

(28.6)

13

(27.7)

 

PD

0

(0.0)

0

(0.0)

2

(10.0)

0

(0.0)

0

(0.0)

4

(57.1)

6

(12.8)

 

Total

2

(3.7)

6

(11.1)

20

(37.0)

8

(14.8)

4

(7.4)

7

(13.0)

47

(100.0)

 
  1. * The patients with evaluable response were calculated by Fisher’s exact test.
  2. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.